These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33397747)

  • 41. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
    Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.
    Ellison G; Ahdesmäki M; Luke S; Waring PM; Wallace A; Wright R; Röthlisberger B; Ludin K; Merkelbach-Bruse S; Heydt C; Ligtenberg MJL; Mensenkamp AR; de Castro DG; Jones T; Vivancos A; Kondrashova O; Pauwels P; Weyn C; Hahnen E; Hauke J; Soong R; Lai Z; Dougherty B; Carr TH; Johnson J; Mills J; Barrett JC
    Hum Mutat; 2018 Mar; 39(3):394-405. PubMed ID: 29215764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
    Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
    Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1/2 missense mutations and the value of in-silico analyses.
    Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
    Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
    Spurdle AB; Healey S; Devereau A; Hogervorst FB; Monteiro AN; Nathanson KL; Radice P; Stoppa-Lyonnet D; Tavtigian S; Wappenschmidt B; Couch FJ; Goldgar DE;
    Hum Mutat; 2012 Jan; 33(1):2-7. PubMed ID: 21990146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic counselor approaches to BRCA1/2 direct-to-consumer genetic testing results.
    Burke S; Mork M; Qualmann K; Woodson A; Jin Ha M; Arun B; Kaulfus M
    J Genet Couns; 2021 Jun; 30(3):803-812. PubMed ID: 33550665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges of Providing Concordant Interpretation of Somatic Variants in Non-Small Cell Lung Cancer: A Multicenter Study.
    Gao P; Zhang R; Li Z; Ding J; Xie J; Li J
    J Cancer; 2019; 10(8):1814-1824. PubMed ID: 31205538
    [No Abstract]   [Full Text] [Related]  

  • 52. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
    Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
    J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    Vos JR; Fakkert IE; de Hullu JA; van Altena AM; Sie AS; Ouchene H; Willems RW; Nagtegaal ID; Jongmans MCJ; Mensenkamp AR; Woldringh GH; Bulten J; Leter EM; Kets CM; Simons M; Ligtenberg MJL; Hoogerbrugge N;
    J Natl Cancer Inst; 2020 Feb; 112(2):161-169. PubMed ID: 31076742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
    Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
    Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
    Padilla N; Moles-Fernández A; Riera C; Montalban G; Özkan S; Ootes L; Bonache S; Díez O; Gutiérrez-Enríquez S; de la Cruz X
    Hum Mutat; 2019 Sep; 40(9):1593-1611. PubMed ID: 31112341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genome analysis and knowledge-driven variant interpretation with TGex.
    Dahary D; Golan Y; Mazor Y; Zelig O; Barshir R; Twik M; Iny Stein T; Rosner G; Kariv R; Chen F; Zhang Q; Shen Y; Safran M; Lancet D; Fishilevich S
    BMC Med Genomics; 2019 Dec; 12(1):200. PubMed ID: 31888639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically impactful differences in variant interpretation between clinicians and testing laboratories: a single-center experience.
    Bland A; Harrington EA; Dunn K; Pariani M; Platt JCK; Grove ME; Caleshu C
    Genet Med; 2018 Mar; 20(3):369-373. PubMed ID: 29240077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reinterpretation of sequence variants: one diagnostic laboratory's experience, and the need for standard guidelines.
    Chisholm C; Daoud H; Ghani M; Mettler G; McGowan-Jordan J; Sinclair-Bourque L; Smith A; Jarinova O
    Genet Med; 2018 Mar; 20(3):365-368. PubMed ID: 29240080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A taxonomic schema of potential pitfalls in clinical variant analysis based on real-world evidence.
    Coovadia A; Boccuto L; Chang Y; DeLuca J
    PLoS One; 2023; 18(11):e0295010. PubMed ID: 38032981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.